A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01336660|
Recruitment Status : Recruiting
First Posted : April 18, 2011
Last Update Posted : July 30, 2018
|Condition or disease||Intervention/treatment||Phase|
|Poisoning by Scorpion Sting||Biological: Equine F(ab')2 antivenom Other: Intensive care support plus placebo||Phase 2 Phase 3|
In an effort to shorten hospital stay and to further decrease mortality, a new antivenom has been developed. This antivenom is a third generation F(ab')2 "fabotherapeutic" agent.It is administered intravenously which should lead to rapid neutralization of circulating venom. This study will demonstrate whether or not use of the new antivenom in children receiving standardized supportive care leads to resolution of the syndrome within 4 hours of treatment.The onset of clinical symptoms following a scorpion envenomation is usually within 5 to 30 minutes following the sting.
Established a classification of the patient status to differentiate a simple scorpion sting from a severe envenomation. A simple sting (class I) is characterized by signs that are local only: pain at the inoculation point, redness, edema, and numbness.
A class II envenomation is characterized by the presence of some systemic signs: hypothermia, hyperthermia, chills, nausea, abdominal pain and diarrhea. Being 15 years old or younger or the presence of priapism, vomiting, sweating, or a body temperature greater than 39°C are factors predictive of severity.
A severe envenomation (class III) is characterized by cardiovascular failure, often leading to death; respiratory failure related to the cardiac failure; and neurologic failure due to hypoxia.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase 2/3 Study for Scorpion North Africa Middle East Envenomation With a Immune F(ab')2 (Equine) Antivenom Alacramyn NAMO. A Randomized, Double-Blind, Placebo-controlled, Prospective and Multicenter Study|
|Actual Study Start Date :||July 21, 2018|
|Estimated Primary Completion Date :||November 2018|
|Estimated Study Completion Date :||March 2019|
Experimental: Equine F(ab')2 antivenom
Intensive care support and Equine F(ab')2 antivenom
Biological: Equine F(ab')2 antivenom
A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
Placebo Comparator: Placebo
Intensive care support plus placebo
Other: Intensive care support plus placebo
Intensive care support as needed plus placebo
- To demonstrate the effectiveness of Alacramyn NAMO in the treatment of scorpion envenomation by reducing the severity of envenomation [ Time Frame: 4 hours after study drug ]Comparison between antivenom and placebo groups of the number of cases showing improvement in class of envenomation.
- Effectiveness of Alacramyn NAMO in the treatment of scorpion envenomation by reducing the severity of envenomation. [ Time Frame: To 16 hours after treatment until discharge time and date ]Decrease in plasma venom levels from baseline to one hour after study drug administration; Respiratory rate (breaths per minute); Heart rate (beats per minute); Dose of dobutamine (cumulative, per hour);Incidence of cardiac failure; Incidence of ventilatory failure; Incidence of neurological failure; Mortality
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01336660
|Contact: Walter Garcia, MD||0052 (1) 55 3733 email@example.com|
|Contact: Rachida Soulaymani, MDfirstname.lastname@example.org|
|CHU Hassan II de Fès||Not yet recruiting|
|Contact: Harrandou Mustapha, MD email@example.com|
|Contact: Sanae Achour, Pr 2120661421282 firstname.lastname@example.org|
|Principal Investigator: Harrandou Mustapha, MD|
|Hôpital Ibn Zohr, Marrakech||Recruiting|
|Contact: Zakar Abdelkader, MD 212661490544 email@example.com|
|Principal Investigator: Zakar Abdelkader, MD|
|Study Director:||Walter Garcia, MD||Instituto Bioclon|
|Study Chair:||Rachida Soulaymani, Pr||Centre Antipoison et de Pharamacovigilance du Maroc|
|Principal Investigator:||Sanae Achour||FES University Hospital|
|Study Chair:||Asmae Khattabi||Ecole Nationale de Santé Publique|